Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

<< Previous

Bullboard Posts

Next >>

Post by 1option1on Jan 16, 2015 10:09am

123 Views

Post# 23327356

NEWS- NioGold Intersects 68.73 g/t Gold Over 4.1 M

NioGold Intersects 68.73 g/t Gold Over 4.1 m on the Marban Deposit

Val d'Or, Quebec / TheNewswire / January 16, 2015 / NioGold Mining Corporation (TSX-V: NOX) (OTCQX: NOXGF) ("NioGold") is pleased to provide the results of the first fifteen (15) diamond drill holes of its current 40,000 meters infill program on the modelled open pit shell of the Marban deposit, located on its 100% owned Marban Block property in the Malartic Gold camp in the Abitibi District of Quebec. The results indicate several new… Read More

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading